Rheumatoid factors induce signaling from B cells, leading to Epstein-Barr virus and B-cell activation

Journal of Virology

Volumn 78, Issue 18, 2004, Pages 9918-9923

  Yang, Lixin ^a   Hakoda, Masayuki ^c   Iwabuchi, Kazuya ^a   Takeda, Tsuyoshi ^b   Koike, Takao ^b   Kamatani, Naoyuki ^d   Takada, Kenzo ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RADIATION EFFECTS RESEARCH FOUNDATION   (Japan)

^d TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B LYMPHOCYTE ANTIGEN; B LYMPHOCYTE RECEPTOR; CD40 LIGAND; IMMUNOGLOBULIN; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; MEMBRANE BOUND IMMUNOGLOBULIN; RHEUMATOID FACTOR; THYMIDINE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE ACTIVATION; BINDING AFFINITY; BURKITT LYMPHOMA; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; INFECTION; LATENT VIRUS INFECTION; LYMPHOBLASTOID CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM; VIRUS ACTIVATION; VIRUS INFECTION; VIRUS TRANSFORMATION;

ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; BURKITT LYMPHOMA; CELL LINE, TUMOR; HERPESVIRUS 4, HUMAN; HUMANS; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, B-CELL; RHEUMATOID FACTOR; SIGNAL TRANSDUCTION; VIRUS ACTIVATION; VIRUS LATENCY;

EID: 4444351644     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.78.18.9918-9923.2004     Document Type: Article

References (43)

1. Alspaugh, M. A., G. Henle, E. T. Lennette, and W. Henle. 1981. Elevated levels of antibodies to Epstein-Barr virus antigens in sera and synovial fluids of patients with rheumatoid arthritis. J. Clin. Investig. 67:1134-1140.
2. Armitage, R. J., W. C. Fanslow, L. Strockbine, T. A. Sato, K. N. Clifford, B. M. Macduff, D. M. Anderson, S. D. Gimpel, T. Davis-Smith, C. R. Maliszewski, E. A. Clark, C. A. Smith, K. H. Grabstein, D. Cosmon, and M. K. Spriggs. 1992. Molecular and biological characterization of a murine ligand for CD40. Nature 357:80-82.
3. + B cells from patients with rheumatoid arthritis. J. Exp. Med. 168:1979-1992.
4. Burastero, S. E., M. Cutolo, V. Dessi, and F. Celada. 1990. Monoreactive and polyreactive rheumatoid factors produced by in vitro Epstein-Barr virus-transformed peripheral blood and synovial B lymphocytes from rheumatoid arthritis patients. Scand. J. Immunol. 32:347-357.
5. Carson, D. A., J. L. Pasquali, C. D. Tsoukas, S. Fong, S. F. Slovin, S. Lawrance, L. Strominger, and J. H. Vaughan. 1981. Physiology and pathology of rheumatoid factors. Springer Semin. Immunopathol. 4:161-179.
6. Carayannopoulos, M. O., K. N. Potter, Y. Li, J. B. Natvig, and J. D. Capra. 2000. Evidence that human immunoglobulin M rheumatoid factors can be derived from the nature antibody pool and undergo an antigen driven immune response in which somatically mutated rheumatoid factor have lower affinities for immunoglobulin G Fc than their germline counterparts. Scand. J. Immunol. 51:327-336.
7. Catalano, M. A., D. A. Carson, S. F. Slovin, D. D. Richman, and J. H. Vaughan. 1979. Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc. Natl. Acad. Sci. USA 76:5825-5828.
8. Chen, F., J. Zou, L. di Renzo, G. Winberg, L. Hu, E. Klein, G. Klein, and I. Ernberg. 1995. A subpopulation of normal B cells latently infected with Epstein-Barr virus resembles Burkitt lymphoma cells in expressing EBNA-1 but not EBNA-2 or LMP1. J. Virol. 69:3752-3758.
9. Daibata, M., R. E. Humphreys, K. Takada, and T. Sairenji. 1990. Activation of latent EBV via anti-IgG-triggered, second messenger pathways in the Burkitt's lymphoma cell line Akata. J. Immunol. 144:4788-4793.
10. DeFranco, A. L. 1997. The complexity of signaling pathways activated by the BCR. Curr. Opin. Immunol. 9:296-308.
11. Ferrell, P. B., C. T. Aitcheson, G. R. Pearson, and E. M. Tan. 1981. Sero-epidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J. Clin. Investig. 67:681-687.
12. Hakoda, M., T. Ishimoto, S. Hayashimoto, K. Inoue, A. Taniguchi, N. Kamatani, and S. Kashiwazaki. 1993. Selective infiltration of B cells committed to the production of monoreactive rheumatoid factor in synovial tissue of patients with rheumatoid arthritis. Clin. Immunol. Immunopathol. 69:16-22.
13. Hampar, B., J. G. Derge, L. M. Martos, and J. L. Walker. 1972. Synthesis of Epstein-Barr virus after activation of the viral genome in a "virus-negative" human lymphoblastoid cell (Raji) made resistant to 5-bromodeoxyuridine. Proc. Natl. Acad. Sci. USA 69:78-82.
14. Jefferis, R., and R. A. Mageed. 1989. The specificity and reactivity of rheumatoid factors with human IgG. Monogr. Allergy 26:45-60.
15. Kieff, E., and A. B. Rickinson. 2002. Epstein-Barr virus, p. 2579-2582. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 4th ed. Lippincott-Raven, Philadelphia, Pa.
16. Konishi, K., S. Maruo, H. Kato, and K. Takada. 2001. Role of Epstein-Barr virus-encoded latent membrane protein 2A on virus-induced immortalization and virus activation. J. Gen. Virol. 82:1451-1456.
17. Krause, A., T. Kamradt, and G. R. Burmester. 1996. Potential infectious agents in the induction of arthritides. Curr. Opin. Rheumatol. 8:203-209.
18. + T lymphocytes. J. Immunol. 159:1783-1793.
19. Levo, Y., R. Fischel, and M. Ehrenfeld. 1981. Circulating immune complexes in patients with rheumatoid arthritis: correlation with disease activity. J. Rheumatol. 8:851-855.
20. Luka, J., B. Kallin, and G. Klein. 1979. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate. Virology 94:228-231.
21. Mannik, M., F. A. Nardella, and E. H. Sasso. 1988. Rheumatoid arthritis. Springer Semin. Immunopathol. 10:115-277.
22. Mark, J. S., C. W. Euler, S. C. Christensen, and J. William. 2003. Activation of rheumatoid factor (RF) B cells and somatic hypermutation outside of germinal centers in autoimmune-prone MRL/lpr mice. Ann. N. Y. Acad. Sci. 987:38-50.
23. Miller, C. L., J. H. Lee, E. Kieff, and R. Longnecker. 1994. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin cross-linking. Proc. Natl. Acad. Sci. USA 91:772-776.
24. Miller, C. L., A. L. Burkhardt, J. H. Lee, B. Stealey, R. Longnecker, J. B. Bolen, and E. Kieff. 1995. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant-negative effects on protein-tyrosine kinases. Immunity 2:155-166.
25. Miyashita, E. M., B. Yang, G. J. Babcock, and D. A. Thorley-Lawson. 1997. Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cells. J. Virol. 71:4882-4891.
26. + B-cell are polyreactive. J. Immunol. 140:4180-4186.
27. Qu, L., and D. Rowe. 1992. Epstein-Barr virus latent gene expression in uncultured peripheral blood lymphocytes. J. ViroI. 66:3715-3724.
28. κ gene directly encodes rheumatoid factor light chains. J. Exp. Med. 164:2119-2124.
29. Robbins, D. L., W. F. Benisek, E. Benjamini, and R. Wister. 1987. Differential reactivity of rheumatoid synovial cells and serum rheumatoid factors to human immunoglobulin G subclasses 1 and 3 and their CH3 domains in rheumatoid arthritis. Arthritis Rheum. 30:489-497.
30. Sculley, T. B., P. J. Walker, D. J. Moss, and J. H. Pope. 1984. Identification of multiple Epstein-Barr virus-induced nuclear antigens with sera from patients with rheumatoid arthritis J. Virol. 52:88-93.
31. Shimizu, N., H. Yoshiyama, and K. Takada. 1996. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J. Virol. 70:7260-7263.
32. Takada, K. 1984. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines. Int. J. Cancer 33:27-32.
33. Takada, K., and Y. Ono. 1989. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J. Virol. 63:445-449.
34. Takeda, T., Y. Mizugaki, L. Matsubara, S. Imai, T. Koike, and K. Takada. 2000. Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum. 43:1218-1225.
35. Tierney, R. J., N. Steven, L. S. Young, and A. B. Rickinson. 1994. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J. Virol. 68:7374-7385.
36. Tosato, G., A. D. Steinberg, R. Yarchoan, C. A. Heilman, S. E. Pike, V. De Seau, and R. M. Blaese. 1984. Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J. Clin. Investig. 73:1789-1795.
37. Tovey, M. G., G. Lenoir, and J. Begon-Lours. 1978. Activation of latent Epstein-Barr virus by antibody to human IgM. Nature 276:270-272.
38. Vaughan, J. H. 1993. Pathogenetic concepts and origins of rheumatoid factor in rheumatoid arthritis. Arthritis Rheum. 36:1-6.
39. Weiss, A., and D. R. Littman. 1994. Signal transduction by lymphocyte antigen receptors. Cell 76:263-274.
40. Williams, D. G., S. P. Moyes, and R. A. Mageed. 1999. Rheumatoid factor isotype switch and somatic mutation variants within rheumatoid arthritis synovium. Immunology 98:123-136.
41. Zimber-Strobl, U., E. Kremmer, F. Grasser, G. Marchall, G. Laux, and G. W. Bornkamm. 1993. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis element of the terminal protein 1 gene promoter. EMBO J. 12:167-175.
42. zur Hausen, H., F. J. O'Neill, U. K. Freese, and E. Hecker. 1978. Persisting oncogenic herpesvirus induced by the tumor promoter TPA. Nature 272:373-375.
43. Zvaifler, N. J. 1973. The immunopathology of joint inflammation in rheumatoid arthritis. Adv. Immunol. 16:265-336.